Journal
NUCLEAR MEDICINE AND BIOLOGY
Volume 30, Issue 4, Pages 417-427Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S0969-8051(03)00019-2
Keywords
radioimmunotherapy; (CU)-C-67; anti-L1-CAM antibody chCE7; renal carcinoma; PET imaging
Ask authors/readers for more resources
In order to optimize radiocopper labeling of anti-L1-CAM antibody chCE7, five bifunctional copper chelators were synthesized and characterized (CPTA-N-hydoxysuccinimide, DO3A-L-p-isothiocyanato-phenylalanine, DOTA-PA-L-p-isocyanato-phenylalanine, DOTA-glycyl-L-p-isocyanato-phenylalanine and DOTA-triglycyl-L-p-isocyanato-phenylalanine). Substitution with more than 11 chelators per antibody molecule was found to influence immunoreactivity and biodistributions of Cu-67-MAb chCE7 significantly. CPTA-labeled antibody achieved the best tumor to normal tissue ratios when biodistributions of the different Cu-67-chCE7 conjugates were assessed in tumor-bearing mice. High resolution PET imaging with Cu-64-CPTA-labeled MAb chCE7 showed uptake in lymph nodes and heterogeneous distribution in tumor xenografts. (C) 2003 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available